Invivo Therapeutics (NVIV) Enrolls New Patient into INSPIRE Study

November 17, 2016 8:20 AM EST
Get Alerts NVIV Hot Sheet
Trade NVIV Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at Oregon Health & Science University (OHSU) in Portland, Oregon. Ahmed M. Raslan, M.D. and Jason J Chang, M.D., Assistant Professors of Neurological Surgery and study investigators, performed surgery and the implantation on the T9 neurologically complete patient approximately 36 hours after the injury occurred.

Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “We are pleased that the patient is doing well and wish them continued recovery. We have nine patients enrolled and in follow up and, because we now have over 25 INSPIRE sites open, expect enrollment to increase in the coming months.”

For more information, please visit the company’s registration site:

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment